PRM36 - Pharmacoeconomic Evaluation of Sorafenib As First-Line Treatment for Advanced Hepatocellular Carcinoma.

Autor:	Naumovska, Z1, Kapedanovska Nestorovska, A1, Grozdanova, A2, Suturkova, L3, Dimovski, A2, Sterjev, Z3
Zdroj:	Value in Health. Oct2017, Vol. 20 Issue 9, pA736-A736. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect